Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

15.5%

93 terminated/withdrawn out of 601 trials

Success Rate

76.9%

-9.6% vs industry average

Late-Stage Pipeline

1%

9 trials in Phase 3/4

Results Transparency

60%

185 of 309 completed trials have results

Key Signals

98 recruiting185 with results71 terminated22 withdrawn

Enrollment Performance

Analytics

Phase 2
188(35.5%)
Phase 1
173(32.6%)
N/A
132(24.9%)
Early Phase 1
28(5.3%)
Phase 3
6(1.1%)
Phase 4
3(0.6%)
530Total
Phase 2(188)
Phase 1(173)
N/A(132)
Early Phase 1(28)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (601)

Showing 20 of 601 trials
NCT07529405Phase 2Not Yet Recruiting

A Study of VG712 in Patients With Mycosis Fungoides

Role: collaborator

NCT06660355Phase 2Recruiting

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Role: lead

NCT04869137Phase 2Active Not Recruiting

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Role: lead

NCT03722407Phase 2Active Not Recruiting

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Role: lead

NCT06476548Phase 1Completed

Mindfulness-Based Ecological Momentary Intervention For Smoking Cessation Among Cancer Survivors

Role: lead

NCT03610971Phase 2Active Not Recruiting

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Role: lead

NCT03370276Phase 1Completed

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Role: lead

NCT03377023Phase 1Active Not Recruiting

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Role: lead

NCT03605927Phase 1Completed

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

Role: lead

NCT06745882Phase 2Recruiting

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Role: lead

NCT02945800Phase 2Completed

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Role: lead

NCT02964078Phase 2Completed

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Role: lead

NCT05628883Phase 1Completed

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Role: lead

NCT02891603Phase 1Completed

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Role: lead

NCT05651828Early Phase 1Recruiting

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Role: lead

NCT06001268Not ApplicableRecruiting

Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)

Role: lead

NCT04562129Phase 2Recruiting

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Role: lead

NCT05692596Active Not Recruiting

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Role: lead

NCT05645146Not ApplicableActive Not Recruiting

Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)

Role: lead

NCT05524935Phase 2Recruiting

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Role: lead